Cargando…

Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor

BACKGROUND: Ossifying fibromyxoid tumor (OFMT) is a rare soft tissue neoplasm of uncertain lineage and intermediate biological potential. It is more common in middle-aged men, usually arising from the deep tissues of the extremities. It is now established that it is a translocation related tumor, mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Provenzano, Salvatore, Raimondi, Alessandra, Bertulli, Rossella M., Colia, Vittoria, Renne, Salvatore L., Collini, Paola, Dagrada, Gianpaolo, Callegaro, Dario, Fiore, Marco, Greco, Francesca G., Casali, Paolo G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745994/
https://www.ncbi.nlm.nih.gov/pubmed/29299229
http://dx.doi.org/10.1186/s13569-017-0086-2
_version_ 1783289021109108736
author Provenzano, Salvatore
Raimondi, Alessandra
Bertulli, Rossella M.
Colia, Vittoria
Renne, Salvatore L.
Collini, Paola
Dagrada, Gianpaolo
Callegaro, Dario
Fiore, Marco
Greco, Francesca G.
Casali, Paolo G.
author_facet Provenzano, Salvatore
Raimondi, Alessandra
Bertulli, Rossella M.
Colia, Vittoria
Renne, Salvatore L.
Collini, Paola
Dagrada, Gianpaolo
Callegaro, Dario
Fiore, Marco
Greco, Francesca G.
Casali, Paolo G.
author_sort Provenzano, Salvatore
collection PubMed
description BACKGROUND: Ossifying fibromyxoid tumor (OFMT) is a rare soft tissue neoplasm of uncertain lineage and intermediate biological potential. It is more common in middle-aged men, usually arising from the deep tissues of the extremities. It is now established that it is a translocation related tumor, most often marked by translocation of PHF1 gene. Surgery is the mainstay of treatment and proves usually curative, although, in rarer cases the disease shows malignant features and tendency to recur both locally and at distant sites. In such cases, no standard treatment exists. CASE PRESENTATION: We report on a case of malignant advanced OFMT of the hand with lung metastases responding to isolated limb perfusion with human recombinant tumor necrosis factor and melphalan and chemotherapy with epirubicin and ifosfamide. CONCLUSIONS: To our knowledge, this is the first report of activity of soft tissue sarcoma-oriented chemotherapy in advanced OFMT.
format Online
Article
Text
id pubmed-5745994
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57459942018-01-03 Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor Provenzano, Salvatore Raimondi, Alessandra Bertulli, Rossella M. Colia, Vittoria Renne, Salvatore L. Collini, Paola Dagrada, Gianpaolo Callegaro, Dario Fiore, Marco Greco, Francesca G. Casali, Paolo G. Clin Sarcoma Res Case Report BACKGROUND: Ossifying fibromyxoid tumor (OFMT) is a rare soft tissue neoplasm of uncertain lineage and intermediate biological potential. It is more common in middle-aged men, usually arising from the deep tissues of the extremities. It is now established that it is a translocation related tumor, most often marked by translocation of PHF1 gene. Surgery is the mainstay of treatment and proves usually curative, although, in rarer cases the disease shows malignant features and tendency to recur both locally and at distant sites. In such cases, no standard treatment exists. CASE PRESENTATION: We report on a case of malignant advanced OFMT of the hand with lung metastases responding to isolated limb perfusion with human recombinant tumor necrosis factor and melphalan and chemotherapy with epirubicin and ifosfamide. CONCLUSIONS: To our knowledge, this is the first report of activity of soft tissue sarcoma-oriented chemotherapy in advanced OFMT. BioMed Central 2017-12-28 /pmc/articles/PMC5745994/ /pubmed/29299229 http://dx.doi.org/10.1186/s13569-017-0086-2 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Provenzano, Salvatore
Raimondi, Alessandra
Bertulli, Rossella M.
Colia, Vittoria
Renne, Salvatore L.
Collini, Paola
Dagrada, Gianpaolo
Callegaro, Dario
Fiore, Marco
Greco, Francesca G.
Casali, Paolo G.
Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor
title Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor
title_full Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor
title_fullStr Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor
title_full_unstemmed Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor
title_short Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor
title_sort response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745994/
https://www.ncbi.nlm.nih.gov/pubmed/29299229
http://dx.doi.org/10.1186/s13569-017-0086-2
work_keys_str_mv AT provenzanosalvatore responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor
AT raimondialessandra responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor
AT bertullirossellam responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor
AT coliavittoria responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor
AT rennesalvatorel responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor
AT collinipaola responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor
AT dagradagianpaolo responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor
AT callegarodario responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor
AT fioremarco responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor
AT grecofrancescag responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor
AT casalipaolog responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor